Scholarlink

Purpose <p>The present study outlines the preparation of lipid polymer hybrid nano-system, designed to deliver Crizotinib (CRZ), aiming to enhance its anticancer efficacy in lung cancer therapy.</p> Methods <p>Self-assembled nanoprecipitation method was used for the preparation of hybrid nanoparticles. BBD (Box-Behnken Design) was employed to optimize the effects of polymer, lipid and surfactant concentration on particle size and entrapment efficiency.</p> Results <p>The optimized hybrid nanoparticles yielded particle size of 94.27 ± 3.15&#xa0;nm and encapsulation efficiency of 81.13 ± 1.26% and exhibiting more than 95% drug release over the period of 72&#xa0;h. The drug release was higher in pH 5.5 compared to pH 6.6 and pH 7.4, this ensured drug release in tumor cell. In-vitro cell viability assessments and confocal imaging demonstrated, that hybrid nanoparticles enhanced cytotoxicity, exhibited good biocompatibility and achieved significant cellular internalization. Furthermore, CRZ loaded hybrid nanoparticles showed superior antiproliferation effects compared to free CRZ in A549 cell line.</p> Conclusion <p>The findings of this investigation suggest that encapsulating CRZ in hybrid nanoparticles offers a promising therapeutic strategy for lung cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring Hybrid Nanoparticles for Crizotinib Delivery in Lung Cancer Treatment; Design, Optimization, In-vitro and Cell Line Evaluation

  • 期刊论文

  • 发表日期：

    2026年2月14日

查看全文
  • Mrunal Rahangdale,
  • Ami Patel,
  • Amit Dabke,
  • Ankit Vankani,
  • Krutika Sawant

摘要

Purpose

The present study outlines the preparation of lipid polymer hybrid nano-system, designed to deliver Crizotinib (CRZ), aiming to enhance its anticancer efficacy in lung cancer therapy.

Methods

Self-assembled nanoprecipitation method was used for the preparation of hybrid nanoparticles. BBD (Box-Behnken Design) was employed to optimize the effects of polymer, lipid and surfactant concentration on particle size and entrapment efficiency.

Results

The optimized hybrid nanoparticles yielded particle size of 94.27 ± 3.15 nm and encapsulation efficiency of 81.13 ± 1.26% and exhibiting more than 95% drug release over the period of 72 h. The drug release was higher in pH 5.5 compared to pH 6.6 and pH 7.4, this ensured drug release in tumor cell. In-vitro cell viability assessments and confocal imaging demonstrated, that hybrid nanoparticles enhanced cytotoxicity, exhibited good biocompatibility and achieved significant cellular internalization. Furthermore, CRZ loaded hybrid nanoparticles showed superior antiproliferation effects compared to free CRZ in A549 cell line.

Conclusion

The findings of this investigation suggest that encapsulating CRZ in hybrid nanoparticles offers a promising therapeutic strategy for lung cancer therapy.